Papers: 10.1177/2472555220973597

https://doi.org/10.1177/2472555220973597

CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target

Cited by: 11
Author(s): Tomas Friman, Alexey Chernobrovkin, Daniel Martinez Molina, Laurence H. Arnold
Published: over 5 years ago

Software Mentions 1